Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"Bad CME" Program May Be Developed By FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency asks physicians to report instances of off-label promotion made during continuing medical education classes.

You may also be interested in...



Can Bad Ad Program's Light Penetrate Murky CME, Clinical Trial Practices?

The "Bad Ad" program already has proven to be a great success in motivating health care providers to report well-known forms of false or misleading drug promotion, such as ads that overstate efficacy and minimize risks, but can it help address more subtle and difficult-to-detect forms of questionable drug promotion, such as those that are hidden in drugmakers' support of professional education and clinical trials?

Can Bad Ad Program's Light Penetrate Murky CME, Clinical Trial Practices?

The "Bad Ad" program already has proven to be a great success in motivating health care providers to report well-known forms of false or misleading drug promotion, such as ads that overstate efficacy and minimize risks, but can it help address more subtle and difficult-to-detect forms of questionable drug promotion, such as those that are hidden in drugmakers' support of professional education and clinical trials?

DDMAC To Cornerstone: Zyflo CR Promotions Need Current Safety Labeling

An FDA advertising violation letter for Cornerstone Therapeutics' asthma therapy Zyflo CR should serve to remind industry that providing outdated safety labeling with promotions is a sure way to draw the agency's regulatory scrutiny

Related Content

Topics

UsernamePublicRestriction

Register

PS070809

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel